Viz.ai Hits Profitability, Reshaping AI's Role in Modern Medicine

SAN FRANCISCO, CA – January 12, 2026 – In a significant turn for the health technology sector, AI-powered care coordination leader Viz.ai announced it has achieved profitability in its core healthcare business, capping a milestone year of record growth and strategic expansion. The company, now a fixture in nearly one-third of all U.S. hospitals, has demonstrated a rare combination of rapid scaling and financial sustainability, signaling a new phase of maturity for artificial intelligence in clinical settings.

Viz.ai's platform, which uses AI to detect disease and streamline communication for care teams, is now deployed in nearly 2,000 hospitals, including a majority of the 50 largest health systems in the United States. This expansive network, built over a decade, provides care support for an estimated 230 million people. The company's 2025 results stand out in a venture-backed landscape often characterized by high cash burn in pursuit of growth, positioning Viz.ai as a potential blueprint for success in the competitive digital health market.

“2025 was a defining year for Viz.ai, with broad adoption across U.S. health systems, profitability in our healthcare business, and rapid expansion with life sciences partners,” said Chris Mansi, MD, CEO and co-founder of Viz.ai, in a statement. “By combining real-time clinical data with deeply trusted workflows, we’re enabling providers and life sciences partners to move faster, operate more efficiently, and ultimately deliver better care to patients.”

A Profitable Model for AI in Healthcare

The announcement of profitability in its healthcare division is a landmark achievement. While the company remains private and does not disclose detailed financials, its path challenges the narrative that AI in healthcare is solely a long-term investment. Viz.ai reached a $1.2 billion “unicorn” valuation in 2022 and has attracted hundreds of millions in funding from major investors like Tiger Global and Google Ventures. Achieving profitability in its primary business line suggests its model of integrating AI into hospital workflows is not just clinically effective but also commercially viable.

This success is built on deep market penetration and high user engagement. The platform's 90% click-through rate on clinical alerts is a testament to its value in high-stakes environments. This level of trust has been pivotal, earning Viz.ai the #1 ranking for AI-powered acute care solutions in the 2025 Black Book Research survey, where it outshone 29 competitors and exceeded user expectations across all performance indicators.

While operating in a competitive field with rivals like RapidAI and Aidoc, Viz.ai has differentiated itself by creating an integrated enterprise platform, Viz.ai One. Instead of offering disparate point solutions, the company encourages health systems to adopt a unified system that can be expanded across various specialties, compounding value and fostering long-term loyalty.

The Unified Platform: From Stroke to Oncology

Central to Viz.ai's strategy is the expansion of its unified platform. The company made significant strides in 2025 by launching two major new products: Viz Oncology and Viz Assist. The Viz Oncology suite extends the platform's proven capabilities in neuroscience and cardiovascular care into the complex world of cancer treatment, aiming to improve disease detection and coordinate care pathways for oncology patients.

Simultaneously, the launch of Viz Assist addresses a pervasive issue in healthcare: administrative burden. This new tool helps clinicians streamline documentation, coordination, and other operational tasks directly within their existing workflow. By integrating these functions, Viz.ai aims to reduce burnout and free up clinicians to focus on patient care. This unified approach is further enhanced through strategic partnerships with enterprise giants Salesforce and Microsoft, embedding its capabilities deeper into the hospital's technological fabric.

This strategy of creating a single, trusted “system of action” is a core differentiator. Hospitals can deploy the platform for a specific need, such as its flagship stroke detection module, and then activate additional capabilities for pulmonology, cardiovascular disease, or oncology as their confidence and needs grow. This model is underpinned by a robust body of clinical evidence, with over 120 peer-reviewed publications and abstracts demonstrating the platform's positive impact on patient outcomes and workflow efficiency.

Bridging the Gap with Life Sciences

Beyond the hospital walls, Viz.ai has quietly built a formidable life sciences business, which it announced has doubled in the past 18 months. The company now partners with 13 life science firms, including seven of the top 30 globally, leveraging its vast, real-time clinical network to revolutionize how new therapies and medical devices reach patients.

The platform's ability to identify eligible patients for specific treatments or clinical trials in real-time is a game-changer for pharmaceutical and medical device companies. It helps solve critical workflow challenges in patient identification, accelerates therapy initiation, and enables direct engagement with healthcare professionals within their established clinical routines. This creates a powerful, AI-enabled go-to-market model for next-generation therapies.

This expansion into life sciences represents a significant new frontier for healthcare AI. By connecting its network of nearly 2,000 hospitals with the engine of therapeutic innovation, Viz.ai is creating a symbiotic ecosystem. Hospitals and patients benefit from faster access to cutting-edge treatments, while life science partners can develop and launch products more efficiently and effectively. The platform is increasingly used to support everything from clinical trial recruitment to post-market surveillance and HCP education, demonstrating the broad applicability of its real-time data layer.

The company’s innovative approach and tangible impact were recognized with a cascade of industry accolades in 2025, including its third consecutive Edison Award for machine learning, a coveted spot on TIME’s list of the World’s Top Health Companies, an R&D 100 Award, and an Aunt Minnie Award, cementing its reputation as a leader in the ongoing digital transformation of healthcare.